Blocking a signal gives human immune cells tumor-linked traits
In laboratory experiments, blocking a signal for 24 hours gave human immune cells features resembling those of immune cells found in tumors.
Our read
Mechanisms- Studied:
- Experiments in human macrophages, 24 hours
- What changed:
- Blocking macrophage migration inhibitory factor induced a senescence-like state resembling tumor-associated macrophages in human macrophages
- The catch:
- Some analyses pooled samples from only three donors
- In the record:
- One of 5 papers on abemaciclib on record: 1 with results in people, 1 in animals.
- Why it’s aging research:
- It studies something that builds up in the body with age.
Editor of record: Boris Djordjevic · AgingResearch.News
Human macrophages, a type of immune cell, were grown from donated blood cells in a laboratory experiment. After six days, researchers used antibodies at 5 micrograms per milliliter to block macrophage migration inhibitory factor, a signal the cells produced themselves. They measured gene activity after six hours and other responses after 24 hours.
Blocking the signal activated p53, a protein that can halt cell division, and NR4A1, a protein that regulates gene activity. The cells entered a state resembling senescence, in which cells stop dividing. Their gene activity resembled that of two groups of tumor-associated macrophages seen across multiple cancers. The enzyme ACSL4 helped these altered macrophages survive and restrained release of an inflammatory signal. In further cell experiments, the cancer drug abemaciclib shifted tumor-like macrophages toward a more inflammatory state.
Why it matters
Senescence is relevant to aging, making its relationship with cancer-associated immune states an important question. The authors identified ACSL4 as a potential therapeutic target.
Caveats
These experiments used cells grown in the lab, not tumors or patients. Some analyses pooled samples from three donors, whose ages and sexes were unknown.
The paper
Innsbruck Medical University
Molecular Biomedicine, Jul 17, 2026, Open access
Comments
Be the first to comment.